Floatz logo

Tislelizumab

Diffuse Large B-Cell Lymphoma

Ningbo No. 1 Hospitalmonoclonal_antibodyPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
81/ 100

Competitive context

252 Active assets in the Diffuse Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Vincristine Sulfate
National Cancer Institute (NCI)
Phase 2/3A
Melphalan
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
Prednisone
Beth Israel Deaconess Medical Center
Phase 4BBB
Adriamycin
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaActive
BB
Indicative · Phase 4
69 / 100
View asset →
classic Hodgkin lymphomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
non-small cell squamous lung carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →